Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Conbercept - Chengdu Kanghong Biological Science & Technology

Next Previous
X
Search
Drug Profile

Conbercept - Chengdu Kanghong Biological Science & Technology

Alternative Names: KH 902; Lumitin; Recombinant human VEGF receptor-Fc fusion protein - Chengdu Kanghong Biological Science & Technology

Latest Information Update: 06 Jun 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chengdu Kanghong Biological Science & Technology
  • Class Eye disorder therapies; Recombinant fusion proteins
  • Mechanism of Action Placenta growth factor inhibitors; Vascular endothelial growth factor A inhibitors; Vascular endothelial growth factor B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Choroidal neovascularisation; Diabetic macular oedema; Wet age-related macular degeneration
  • Phase III Retinal oedema
  • Phase II Retinoblastoma
  • No development reported Corneal disorders

Most Recent Events

  • 06 Feb 2023 Launched for Choroidal neovascularisation in China (Intravitreous) as of February 2023
  • 06 Feb 2023 Launched for Diabetic macular oedema in China (Intravitreous) as of February 2023
  • 06 Feb 2023 Registered for Choroidal neovascularisation in China (Intravitreous) as of February 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top